NV-ALVARIA.
13.9.2022 15:01:49 CEST | Business Wire | Press release
Today, Alvaria, Inc. is pleased to announce the successful deployment of Alvaria Cloud™ in Google Cloud Platform (GCP). Adding GCP to their current offerings of AWS and Azure expands the available public cloud options Alvaria provides to support customer experience (CX) and employee engagement (EX) strategies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220913005584/en/
Alvaria CEO, Jeff Cotten rehearses "The Modern Contact Center" for opening day at ACE 2022 where he unveils a new engagement framework, The Alvaria Enterprise Modernization Journey (Photo: Business Wire)
Providing multiple public cloud selections, including GCP, is a part of the commitment Alvaria has made to provide choice for customers in order to meet their business objectives with the proper products and services. As an enterprise CCaaS vendor, Alvaria now provides industry leading support to help enterprise brands with complex and specific configuration requirements evolved to meet the needs of rapidly evolving customer expectations.
ACE 2022, Alvaria U kicks off at 9:00 AM PDT with The Modern Contact Center, an address from Chief Executive Officer, Jeff Cotten. He will unveil a new engagement framework, The Alvaria Enterprise Modernization Journey.
“We will assist customers through a process of determining business and technology objectives, with a goal of understanding where they are today and the desired end state,” said Jeff Cotten. “We will then map the best fit of products and services that align to their business goals because with Alvaria you are not going to hear and see a one-size-fits-all approach. We aim to enable choice and flexibility.”
In addition to the CEO Address, Alvaria has a full agenda planned for former Aspect Software, Noble Systems and Alvaria customers and partners including new product demonstrations, insights from industry experts, as well as product tips and tricks and a special keynote, Customer Obsession: How to Satisfy Inherently Unsatisfiable Customers, by Gibson Biddle, Entrepreneur, Advisor, Former Netflix VP Product Management.
Core to the success of ACE each year is the participation of Alvaria Partners. Alvaria would like to thank a select group of partners who have sponsored the event: Call Design, Communik.me, CS Infocomm, ITFor, Resolutte, Rich Communication Technology, Rising Interactions and Waterfield Technologies. Furthermore, this year, Alvaria introduced the ACE Partner Certified Seller track, designed to enable Alvaria partners worldwide with tools to win business.
Alvaria SVP of Global Marketing, Colleen Sheley said, “The pandemic has greatly emphasized the need for enterprises to be resilient, secure and continue to deliver exceptional customer experiences. Brands want to invest in accelerating their consumer technology initiatives and now with the deployment of Alvaria Cloud in GCP there's now less friction and more choice than ever before.”
Registration for the virtual event is still open. Get complimentary access with code: VIRTUAL-ACE22-BEMYGUEST
To register, please visit www.alvaria.com/ace
Alvaria was founded through the merger of Aspect Software and Noble Systems. We are the world leader in enterprise-scale customer experience (CX) and workforce engagement management (WEM) solutions. Our name is derived from Latin for “hives” – nature’s perfect form for millions of years – bringing you solutions that are scalable, resilient and secure, with efficiency, speed and pinpoint accuracy. ALVARIA™. Reshaping Customer Experience™. For more information, please visit www.alvaria.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005584/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom